Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination

Male 0301 basic medicine [SDV]Life Sciences [q-bio] Paul Gorochov Antibodies, Viral Cohort Studies [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases Original Investigation [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases Desaint Vaccination Middle Aged France Gorochov [SDV] Life Sciences [q-bio] [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases [SDV.IMM]Life Sciences [q-bio]/Immunology Ninove Female France 2019-nCoV Vaccine mRNA-1273 Adult COVID-19 Vaccines [SDV.IMM] Life Sciences [q-bio]/Immunology Paul Villejuif Ropers Kieny Lebbah Rekacewicz 03 medical and health sciences [SDV.IMM.VAC] Life Sciences [q-bio]/Immunology/Vaccinology Tartour Durier Humans Hupé Saliva Immunity, Mucosal BNT162 Vaccine Aged Vieillard Lachatre); INSERM SC10-US019 SARS-CoV-2 COVID-19 Launay Desaint Vieillard Rekacewicz Lachatre); INSERM SC10-US019 Villejuif France Gorochov Ropers Launay Durier Desaint Vieillard Lachatre Parfait Hupé Ninove Kieny Tartour Paul Gorochov Ropers Lebbah Desaint Parfait Tartour Paul Immunoglobulin A [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie Immunoglobulin G [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology Lachatre [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie Launay [SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology Parfait
DOI: 10.1001/jamanetworkopen.2024.8051 Publication Date: 2024-04-23T15:01:59Z
ABSTRACT
Importance There is still considerable controversy in the literature regarding capacity of intramuscular messenger RNA (mRNA) vaccination to induce a mucosal immune response. Objective To compare serum and salivary IgG IgA levels among mRNA-vaccinated individuals with or without previous SARS-CoV-2 infection. Design, Setting, Participants In this cohort study, SARS-CoV-2–naive participants those infection were consecutively included CoviCompare P M mRNA trials followed up day 180 after either BNT162b2 (Pfizer-BioNTech) vaccine mRNA-1273 (Moderna) at beginning COVID-19 campaign (from February 19 June 8, 2021) France. Data analyzed from October 25, 2022, July 13, 2023. Main Outcomes Measures An ultrasensitive digital enzyme-linked immunosorbent assay was used for comparison spike-specific levels. Spike-specific secretory level also quantified selected times. Results A total 427 3 groups: prior who received 1 single dose (n = 120) 2 doses 172) 135). The median age 68 (IQR, 39-75) years, 228 (53.4%) men. saliva increased injections individuals. After vaccination, SARS-CoV-2–specific levels, normalized respect significantly higher infection, as compared most responsive recipients (median 155 × 10 −5 vs 37 29; 107 54 57; 104 70 [ < .001]). contrast, 1, BNT162b2-vaccinated group only 57 (36 49 .01]). Bona fide multimeric antigenic stimulations optical density, 0.36 [IQR, 0.16-0.63] 0.16 0.10-0.22]; .001). Conclusions Relevance findings study suggest that associated immunity but much lower than previously infected Further studies are needed determine association between specific prevention transmission.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (18)
CITATIONS (15)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....